Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Citation:||Cardiovascular Drug Reviews, 2007; 25(1):76-97|
|Houman Ashrafian, John D. Horowitz, Michael P. Frenneaux|
|Abstract:||Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as an anti-anginal drug in the 1970s. Despite its success, its use diminished due to the occurrence of poorly understood side effects including neurotoxicity and hepatotoxicity in a small proportion of patients. Recently, perhexiline's mechanism of action and the molecular basis of its toxicity have been elucidated. Perhexiline reduces fatty acid metabolism through the inhibition of carnitine palmitoyltransferase, the enzyme responsible for mitochondrial uptake of long-chain fatty acids. The corresponding shift to greater carbohydrate utilization increases myocardial efficiency (work done per unit oxygen consumption) and this oxygen-sparing effect explains its antianginal efficacy. Perhexiline's side effects are attributable to high plasma concentrations occurring with standard doses in patients with impaired metabolism due to CYP2D6 mutations. Accordingly, dose modification in these poorly metabolizing patients identified through therapeutic plasma monitoring can eliminate any significant side effects. Herein we detail perhexiline's pharmacology with particular emphasis on its mechanism of action and its side effects. We discuss how therapeutic plasma monitoring has led to perhexiline's safe reintroduction into clinical practice and how recent clinical data attesting to its safety and remarkable efficacy led to a renaissance in its use in both refractory angina and chronic heart failure. Finally, we discuss the application of pharmacogenetics in combination with therapeutic plasma monitoring to potentially broaden perhexiline's use in heart failure, aortic stenosis, and other cardiac conditions.|
|Keywords:||Liver; Animals; Humans; Neurotoxicity Syndromes; Heart Diseases; Aortic Valve Stenosis; Myocardial Ischemia; Angina Pectoris; Perhexiline; Cytochrome P-450 CYP2D6; Carnitine O-Palmitoyltransferase; Fatty Acids; Calcium Channel Blockers; Vasodilator Agents; Enzyme Inhibitors; Drug Monitoring; Treatment Outcome; Molecular Structure; Mutation; Lipid Metabolism; Heart Failure; Chemical and Drug Induced Liver Injury|
|Description:||The definitive version is available at www.blackwell-synergy.com|
|Provenance:||From the beginning of 2008 Cardiovascular Drug Reviews will be known as Cardiovascular Therapeutics|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.